News & Updates
Filter by Specialty:
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024
ART discontinuation tied to toxicity, disease progression in mCRPC patients
Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.
ART discontinuation tied to toxicity, disease progression in mCRPC patients
07 Jun 2024
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.